Latest Breaking News On - பாரம்பரியம் மருத்துவ ஆராய்ச்சி நிறுவனம் புலனாய்வாளர் - Page 2 : comparemela.com

Capsida Biotherapeutics Inc., a Thousand Oaks, CA-based biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, raised $140m in Series A funding. Backers included Versant Ventures and Westlake Village BioPartners, which together provided $50m. Capsida also announced a multi-year strategic collaboration and option agreement with AbbVie that provides $90m in up front and equity investment capital in addition to potential future option, development and commercial milestone payments. The collaboration is aimed at developing targeted gene therapies for three programs in serious neurodegenerative diseases. Led by Robert Cuddihy, M.D., chief executive officer, Capsida provides an AAV engineering platform that generates capsids optimized to target specific tissue types and limits transduction of tissues and cell types that are not relevant to the target disease, allo

Thousand oaksUnited statesRobert cuddihyViviana gradinaruChrissy chen institute for neuroscience at caltechCapsida biotherapeutics incHeritage medical research institute investigatorVersant venturesWestlake village biopartnersBiological engineeringCellular neuroscienceChrissy chen instituteஆயிரம் ஓக்ஸ்ஒன்றுபட்டது மாநிலங்களில்கிறிஸி சென் நிறுவனம் க்கு நரம்பியல் இல் கால்டெக்பாரம்பரியம் மருத்துவ ஆராய்ச்சி நிறுவனம் புலனாய்வாளர்